Search Results

Melior Discovery, Inc. announced that it has been selected as the CRO of the Year by Life Sciences Review magazine.

Melior Discovery, Inc. (Melior) announced today significant additions to its management organization.

This webinar explores the pivotal role of patent data in overcoming the data challenges faced by generative AI models in drug discovery, particularly for biologics. Watch now.

Melior Pharmaceuticals (Melior) announced that it completed a definitive licensing agreement with Adhera Therapeutics, Inc . (OTCPK: ATRX; Adhera) for Melior’s Parkinson’s disease (PD) candidate, MLR-1019 (armesocarb).

AbTherx, Inc., a biotechnology company with innovative technologies that enable and accelerate antibody discovery, announced the opening of its new antibody discovery technologies research center.

Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) is pleased to announce that it has entered into an agreement for the assignment of Adhera Therapeutics, Inc.’s (“Adhera’s”) rights to tolimidone (formerly coded MLR-1023) under an exclusive, worldwide, sub-licensable license from Melior Pharmaceuticals I, Inc. (“Melior”) to develop, manufacture, commercialize or otherwise exploit tolimidone.

Melior Pharmaceuticals (Melior) announced that it has signed a “letter of intent” with Adhera Therapeutics, Inc . (OTCPK: ATRX; Adhera) for the acquisition of Melior’s Parkinson’s disease (PD) candidate, MLR-1019 (armesocarb).